| First Author | Shen Q | Year | 2005 |
| Journal | Mutat Res | Volume | 576 |
| Issue | 1-2 | Pages | 93-110 |
| PubMed ID | 15888345 | Mgi Jnum | J:100623 |
| Mgi Id | MGI:3588944 | Doi | 10.1016/j.mrfmmm.2004.10.013 |
| Citation | Shen Q, et al. (2005) Transgenic mouse models for the prevention of breast cancer. Mutat Res 576(1-2):93-110 |
| abstractText | Breast cancer prevention research has made remarkable progress in the past decade. Much of this progress has come from clinical trials. However, in the future to test the many promising agents that are now available, pre-clinical models of breast cancer are needed. Such models are now available. Useful models include rat and mouse models, particularly, the genetically engineered mice (GEM). Many transgenic mouse models have been generated by manipulating growth factors and their receptors, cell cycle regulators, signal transduction pathways, cellular differentiation, oncogenes and tumor suppressor genes. The transgenes are induced to express in the mouse mammary glands under the control of various transgenic promoters, which have respective characteristics in expression pattern and other biological attributes. These models are providing invaluable insight on the molecular mechanisms of breast tumorigenesis. In this review, we discuss the relative relevance of the most commonly used transgenic mouse models for breast cancer prevention studies, and provide examples of how these transgenic models can be used to conduct cancer prevention research. Due to the multi-factor, multi-step nature of breast cancer, many factors should be incorporated into a valid prevention study. However, many barriers to progress must be overcome, including access to and availability of new cancer preventive drugs, and difficulties in conducting studies of combinations of preventive agents. |
